Head to Head Review: China Cord Blood Corporation (CO) vs. Its Competitors
China Cord Blood Corporation (NYSE: CO) is one of 49 public companies in the “Healthcare Facilities & Services” industry, but how does it compare to its peers? We will compare China Cord Blood Corporation to similar companies based on the strength of its institutional ownership, risk, dividends, analyst recommendations, valuation, profitability and earnings.
Volatility & Risk
China Cord Blood Corporation has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, China Cord Blood Corporation’s peers have a beta of 1.01, meaning that their average share price is 1% more volatile than the S&P 500.
Earnings & Valuation
This table compares China Cord Blood Corporation and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|China Cord Blood Corporation||$124.21 million||$53.01 million||40.14|
|China Cord Blood Corporation Competitors||$5.72 billion||$906.68 million||38.74|
China Cord Blood Corporation’s peers have higher revenue and earnings than China Cord Blood Corporation. China Cord Blood Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares China Cord Blood Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|China Cord Blood Corporation||22.07%||8.64%||3.50%|
|China Cord Blood Corporation Competitors||6.86%||0.02%||0.39%|
This is a breakdown of recent ratings for China Cord Blood Corporation and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|China Cord Blood Corporation||0||0||0||0||N/A|
|China Cord Blood Corporation Competitors||258||1480||1913||38||2.47|
As a group, “Healthcare Facilities & Services” companies have a potential downside of 7.95%. Given China Cord Blood Corporation’s peers higher probable upside, analysts plainly believe China Cord Blood Corporation has less favorable growth aspects than its peers.
Insider & Institutional Ownership
13.3% of China Cord Blood Corporation shares are held by institutional investors. Comparatively, 73.5% of shares of all “Healthcare Facilities & Services” companies are held by institutional investors. 12.8% of shares of all “Healthcare Facilities & Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
China Cord Blood Corporation peers beat China Cord Blood Corporation on 7 of the 10 factors compared.
China Cord Blood Corporation Company Profile
China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. It also tests, processes and stores donated cord blood, and provides matching services to the public for a fee. The Company provides cord blood processing and storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies, such as cord blood transplants. It also preserves cord blood units donated by the public; provides matching services on such donated units, and delivers matching units to patients in need of transplants. As of March 31, 2016, the Company had three operating cord blood banks.
Receive News & Stock Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related stocks with our FREE daily email newsletter.